Literature DB >> 17937890

[Gas-6 and protein S: vitamin K-dependent factors and ligands for the TAM tyrosine kinase receptors family].

Omar Benzakour1, Aurore Gely, Romain Lara, Valérie Coronas.   

Abstract

The gamma-carboxyglutamate-containing proteins are a family of secreted vitamin K-dependent proteins in which some glutamyl residues are post-translationally modified to gamma-carboxyglutamic acid residues. A vitamin K-dependent gamma-glutamyl carboxylase enzyme catalyses this post-translational modification. The gamma-carboxylase reaction requires vitamin K in its reduced form, vitamin K hydroquinone, and generates gamma-carboxyglutamate and vitamin K 2,3,-epoxide which is then recycled back to the hydroquinone form by a vitamin K reductase system. Warfarin blocks the vitamin K cycle and hence inhibits the gamma-carboxylase reaction, and this property of Warfarin has led to its wide use in anticoagulant therapy. Until recently, interest in vitamin K-dependent proteins was mostly restricted to the field of hematology. However, the discovery that the anti-coagulant factor protein S and its structural homologue Gas6 (growth arrest-specific gene 6), two vitamin K-dependent proteins, are ligands for the Tyro3/Axl/Mer family of related tyrosine kinase receptors has opened up a new area of research. Moreover, the phenotypes associated with the invalidation of genes encoding vitamin K-dependent proteins or their receptors revealed their implication in regulating phagocytosis during many cell differentiation phenomena such as retinogenesis, neurogenesis, osteogenesis, and spermatogenesis. Additionally, protein S was identified as the major factor responsible for serum-stimulated phagocytosis of apoptotic cells. Therefore, the elucidation of the molecular mechanisms underlying the role of vitamin K-dependent proteins in regulating apoptotic cell phagocytosis may lead to a better understanding of the physiopathology of cell differentiation and could form the framework of new therapeutic strategies aiming at a selective targeting of cell phagocytosis associated pathologies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17937890     DOI: 10.1051/medsci/20072310826

Source DB:  PubMed          Journal:  Med Sci (Paris)        ISSN: 0767-0974            Impact factor:   0.818


  5 in total

1.  Increased MerTK expression in circulating innate immune cells of patients with septic shock.

Authors:  Caroline Guignant; Fabienne Venet; Séverine Planel; Julie Demaret; Aurélie Gouel-Chéron; Christophe Nougier; Arnaud Friggeri; Bernard Allaouchiche; Alain Lepape; Guillaume Monneret
Journal:  Intensive Care Med       Date:  2013-07-09       Impact factor: 17.440

2.  Baseline Plasma Gas6 Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients.

Authors:  Stelvio Tonello; Manuela Rizzi; Erica Matino; Martina Costanzo; Giuseppe Francesco Casciaro; Alessandro Croce; Eleonora Rizzi; Erika Zecca; Anita Pedrinelli; Veronica Vassia; Raffaella Landi; Mattia Bellan; Luigi Mario Castello; Rosalba Minisini; Venkata Ramana Mallela; Davide D'Onghia; Gian Carlo Avanzi; Mario Pirisi; Daniele Lilleri; Pier Paolo Sainaghi
Journal:  Dis Markers       Date:  2022-04-29       Impact factor: 3.464

3.  Axl as a downstream effector of TGF-β1 via PI3K/Akt-PAK1 signaling pathway promotes tumor invasion and chemoresistance in breast carcinoma.

Authors:  Yanyan Li; Li Jia; Chen Liu; Yanxin Gong; Dongliang Ren; Ning Wang; Xu Zhang; Yongfu Zhao
Journal:  Tumour Biol       Date:  2014-10-21

4.  Identification of pAKT as a pharmacodynamic marker for MER kinase in human melanoma G361 cells.

Authors:  Yaoyu Chen; Margaret Favata; Michelle Pusey; Jun Li; Yvonne Lo; Min Ye; Richard Wynn; Xiaozhao Wang; Wenqing Yao; Yingnan Chen
Journal:  Biomark Res       Date:  2020-02-04

Review 5.  The role of phosphatidylserine recognition receptors in multiple biological functions.

Authors:  Mehri Bemani Naeini; Vanessa Bianconi; Matteo Pirro; Amirhossein Sahebkar
Journal:  Cell Mol Biol Lett       Date:  2020-03-26       Impact factor: 5.787

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.